1. Home
  2. PMAX vs VIVS Comparison

PMAX vs VIVS Comparison

Compare PMAX & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$0.48

Market Cap

3.4M

Sector

N/A

ML Signal

HOLD

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$0.15

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
VIVS
Founded
2019
2007
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
2.1M
IPO Year
2024
2010

Fundamental Metrics

Financial Performance
Metric
PMAX
VIVS
Price
$0.48
$0.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.2M
656.4K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,603,000.00
Revenue This Year
N/A
$228,144.28
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.82
52 Week Low
$0.20
$0.15
52 Week High
$4.81
$3.40

Technical Indicators

Market Signals
Indicator
PMAX
VIVS
Relative Strength Index (RSI) 33.87 29.48
Support Level $0.28 N/A
Resistance Level $2.69 $0.30
Average True Range (ATR) 0.07 0.02
MACD -0.01 0.00
Stochastic Oscillator 6.31 8.92

Price Performance

Historical Comparison
PMAX
VIVS

About PMAX Powell Max Limited

Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

Share on Social Networks: